The Guardian view on high-end science in the National Health Service
The genome project and improving ambulance response times both matterThe NHS has an extraordinary record of medical innovation. The link between smoking and lung cancer, the first baby born through IVF and the first heart, lung and liver transplant were all achievements of the health service. Now the 11 hospital trusts which will pioneer the 100,000 genome project have been named. They will recruit participants in an ambitious attempt to sequence the genetic make-up of up to 100,000 NHS patients, creating a database to allow researchers to identify the links between genetic variations and cancers and other rare diseases. At last the high hopes of gene sequencing may be translated into practical medicine. There is talk of genetics as a diagnostic tool, the development of personalised medicine and new, precision-targeted drugs that would amount to a revolution in healthcare. As the health secretary, Jeremy Hunt, argued in a speech last month, the NHS is remarkably good at advanced medical science.This tradition of medical creativity sits awkwardly with the other image of the NHS, as a sclerotic organisation that is as bad at delivering new ways of managing process as it is good at bringing in new ways of treating people. This may not be fair. Restraining the cost of healthcare is a global preoccupation, and the NHS delivers better outcomes for less money than any other comparable system. All the same, the unique politics of the NHS can lead to damaging contortions, as the weeke...
Authors: Goret CC, Goret NE, Ozkan OF, Karaayvaz M Abstract Foreign body reactions may develop against exogenous or certain endogenous materials. Cases of suture granuloma that develop against nonabsorbable suture material are rare complications of thyroid surgery. Because of these postoperative complications, a history of cancer prior to the operation suggests recurrence of cancer. Appropriate clinical, radiological, and pathological evaluation is highly important in such cases. Postoperative foreign bodies may remain undetected for years, but they sometimes cause lethal complications. KEY WORDS: Cancer mimick...
Authors: Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M Abstract BACKGROUND: Programmed cell death-ligand 1 (PD-L1) is a checkpoint receptor that facilitates immune evasion by tumor cells, through interaction with programmed cell death-1 (PD-1), a receptor expressed by T-cells. Durvalumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 interaction with PD-1 on T-cells, countering the tumor's immune-evading tactics. Phase I/II studies demonstrated durable responses and manageable tolerability in heavily pre-treated patients with non-sma...
When a patient has an inherited cancer-associated gene, it is desirable, but not easy, to have other family members tested. Using a commercial lab to circumvent nettlesome privacy regulations may help.Medscape Medical News
PANCREATIC cancer doesn ’t have any specific causes, but there are various risk factors which could increase the chance of developing the disease. Having diabetes is one of them.
We report dermoscopic findings of early, non-ulcerated livedoid vasculopathy in five patients. A mixture of ivory-white atrophic areas with multiple erythematous papules in the center of the lesions is characteristic. With dermoscopy, these papules correspond to glomerular vessels. In the periphery of the lesions some telangiectatic linear vessels complete the picture, although they could be absent in some patients. PMID: 30244265 [PubMed - in process]
THE first UK patient has received radiotherapy using a machine which could one day cure some cancers in a single treatment.
Barry Dolling, 65, from Selsdon in Surrey, has become the first person in the UK to receive radiotherapy treatment from the MR Linac machine at the Royal Marsden in London.
PMID: 30243508 [PubMed - in process]
Annual detection of prostate cancer in men 70 and older costs Medicare an estimated $1.2 billion every three years, and most costs are treatment-related, according to new findings.Reuters Health Information
Effective first-line chemotherapy and targeted therapy in patients with metastatic breast cancer may offer the possibility of cure.Chinese Clinical Oncology
More News: Babies | Babies Heart Conditions | Biomedical Science | Cancer | Cancer & Oncology | Cardiology | Databases & Libraries | Genetics | Health | Heart | Heart Transplant | Hospitals | Liver | Liver Transplant | Lung Cancer | Lung Transplant | National Health Service (NHS) | Politics | Rare Diseases | Research | Science | Smokers | Transplant Surgery | Transplants | UK Health | Urology & Nephrology